23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Lineage Cell Therapeutics, Inc. › 2025-2026

Lineage Cell Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Lineage Cell Therapeutics, Inc.’s Form 8-K, filed June 12, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 9Ballot items
  • 101Asset managers, any item
  • 334Fund votes
  • June 10, 2026Meeting date

Results at a glance

Meeting of June 10, 2026: 9 items on Lineage Cell Therapeutics, Inc.’s Form 8-K, filed June 12, 2026: 7 elected · 2 approved.

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Lineage Cell Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Lineage Cell Therapeutics, Inc.

These tallies are Lineage Cell Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Lineage Cell Therapeutics, Inc. — official shareholder meeting results, meeting held June 10, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Michael H. Mulroy 90,383,337---- 1,201,44873,917,854 99%Elected—
Elect Director: Dipti Amin 90,428,362---- 1,156,42373,917,854 99%Elected—
Elect Director: Deborah Andrews 90,328,622---- 1,256,16373,917,854 99%Elected—
Elect Director: Angus C. Russell 90,464,859---- 1,119,92673,917,854 99%Elected—
Elect Director: Neal C. Bradsher 90,514,702---- 1,070,08373,917,854 99%Elected—
Elect Director: Brian M. Culley 89,917,990---- 1,666,79573,917,854 98%Elected—
Elect Director: Anula Jayasuriya 90,549,317---- 1,035,46873,917,854 99%Elected—
2. The appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 163,825,928659,6701,017,041 ---- 99.6%Approved—
3. The compensation paid to the Company's named executive officers, as set forth in the Proxy Statement 88,328,1682,600,932655,685 --73,917,854 97%Approved—

This meeting is also recorded here as June 9, 2026; both records come from the same filing, so the date should be checked against it.

Source: Lineage Cell Therapeutics, Inc., Form 8-K, filed with the SEC on June 12, 2026 — read the filing on EDGAR.

How asset managers voted at the Lineage Cell Therapeutics, Inc. 2025-2026 meeting

101 asset managers disclosed a vote on at least one Lineage Cell Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Angus C. Russell

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 90,464,859WITHHELD: 1,119,926

Prior year: 98.9% for (June 26, 2025 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 10 asset managers

Description as filed by funds: To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Angus C. Russell

Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Angus C. Russell”): 90,464,859 for, 1,119,926 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Shareholders elected the seven nominees named below to the Company's board to hold office until the Company's 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 10 asset managers below reported 9,494,089 for, 18,058 withheld, 4 abstained.

FOR
FOR: 9,494,089ABSTAIN: 4WITHHOLD: 18,058
Largest asset managers voting on “To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respecti” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard7,707,2570 418,058For
BlackRock1,143,7850 00For
Fidelity607,8180 00For
Goldman Sachs9,7480 00For
BRIDGEWAY FUNDS INC9,6000 00For
Charles Schwab6,5690 00For
Lincoln Financial4,3000 00For
John Hancock3,9950 00For
Guggenheim7470 00For
Victory Capital2700 00For

Elect Director: Anula Jayasuriya

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 90,549,317WITHHELD: 1,035,468

Prior year: 98.6% for (June 26, 2025 meeting) ▲ 0.3 pts

Details: description as filed, official tally, votes by 10 asset managers

Description as filed by funds: To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Anula Jayasuriya

Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Anula Jayasuriya”): 90,549,317 for, 1,035,468 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Shareholders elected the seven nominees named below to the Company's board to hold office until the Company's 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 10 asset managers below reported 9,512,147 for, 3 abstained.

FOR
FOR: 9,512,147ABSTAIN: 3
Largest asset managers voting on “To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respecti” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard7,725,3150 30For
BlackRock1,143,7850 00For
Fidelity607,8180 00For
Goldman Sachs9,7480 00For
BRIDGEWAY FUNDS INC9,6000 00For
Charles Schwab6,5690 00For
Lincoln Financial4,3000 00For
John Hancock3,9950 00For
Guggenheim7470 00For
Victory Capital2700 00For

Elect Director: Brian M. Culley

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 89,917,990WITHHELD: 1,666,795

Prior year: 98.1% for (June 26, 2025 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 10 asset managers

Description as filed by funds: To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Brian M. Culley

Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Brian M. Culley”): 89,917,990 for, 1,666,795 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Shareholders elected the seven nominees named below to the Company's board to hold office until the Company's 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 10 asset managers below reported 9,494,087 for, 18,058 withheld, 6 abstained.

FOR
FOR: 9,494,087ABSTAIN: 6WITHHOLD: 18,058
Largest asset managers voting on “To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respecti” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard7,707,2550 618,058For
BlackRock1,143,7850 00For
Fidelity607,8180 00For
Goldman Sachs9,7480 00For
BRIDGEWAY FUNDS INC9,6000 00For
Charles Schwab6,5690 00For
Lincoln Financial4,3000 00For
John Hancock3,9950 00For
Guggenheim7470 00For
Victory Capital2700 00For

Elect Director: Deborah Andrews

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 90,328,622WITHHELD: 1,256,163

Prior year: 98.1% for (June 26, 2025 meeting) ▲ 0.5 pts

Details: description as filed, official tally, votes by 10 asset managers

Description as filed by funds: To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Deborah Andrews

Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Deborah Andrews”): 90,328,622 for, 1,256,163 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Shareholders elected the seven nominees named below to the Company's board to hold office until the Company's 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 10 asset managers below reported 9,494,089 for, 18,058 withheld, 4 abstained.

FOR
FOR: 9,494,089ABSTAIN: 4WITHHOLD: 18,058
Largest asset managers voting on “To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respecti” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard7,707,2570 418,058For
BlackRock1,143,7850 00For
Fidelity607,8180 00For
Goldman Sachs9,7480 00For
BRIDGEWAY FUNDS INC9,6000 00For
Charles Schwab6,5690 00For
Lincoln Financial4,3000 00For
John Hancock3,9950 00For
Guggenheim7470 00For
Victory Capital2700 00For

Elect Director: Dipti Amin

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 90,428,362WITHHELD: 1,156,423

Prior year: 98.9% for (June 26, 2025 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 10 asset managers

Description as filed by funds: To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Dipti Amin

Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Dipti Amin”): 90,428,362 for, 1,156,423 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Shareholders elected the seven nominees named below to the Company's board to hold office until the Company's 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 10 asset managers below reported 9,512,146 for, 4 abstained.

FOR
FOR: 9,512,146ABSTAIN: 4
Largest asset managers voting on “To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respecti” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard7,725,3140 40For
BlackRock1,143,7850 00For
Fidelity607,8180 00For
Goldman Sachs9,7480 00For
BRIDGEWAY FUNDS INC9,6000 00For
Charles Schwab6,5690 00For
Lincoln Financial4,3000 00For
John Hancock3,9950 00For
Guggenheim7470 00For
Victory Capital2700 00For

Elect Director: Michael H. Mulroy

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 90,383,337WITHHELD: 1,201,448

Prior year: 98.8% for (June 26, 2025 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 10 asset managers

Description as filed by funds: To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Michael H. Mulroy

Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Michael H. Mulroy”): 90,383,337 for, 1,201,448 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Shareholders elected the seven nominees named below to the Company's board to hold office until the Company's 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 10 asset managers below reported 9,494,089 for, 18,058 withheld, 4 abstained.

FOR
FOR: 9,494,089ABSTAIN: 4WITHHOLD: 18,058
Largest asset managers voting on “To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respecti” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard7,707,2570 418,058For
BlackRock1,143,7850 00For
Fidelity607,8180 00For
Goldman Sachs9,7480 00For
BRIDGEWAY FUNDS INC9,6000 00For
Charles Schwab6,5690 00For
Lincoln Financial4,3000 00For
John Hancock3,9950 00For
Guggenheim7470 00For
Victory Capital2700 00For

Elect Director: Neal C. Bradsher

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 90,514,702WITHHELD: 1,070,083

Prior year: 98.4% for (June 26, 2025 meeting) ▲ 0.5 pts

Details: description as filed, official tally, votes by 10 asset managers

Description as filed by funds: To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Neal C. Bradsher

Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Neal C. Bradsher”): 90,514,702 for, 1,070,083 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Shareholders elected the seven nominees named below to the Company's board to hold office until the Company's 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 10 asset managers below reported 9,494,089 for, 18,058 withheld, 4 abstained.

FOR
FOR: 9,494,089ABSTAIN: 4WITHHOLD: 18,058
Largest asset managers voting on “To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respecti” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard7,707,2570 418,058For
BlackRock1,143,7850 00For
Fidelity607,8180 00For
Goldman Sachs9,7480 00For
BRIDGEWAY FUNDS INC9,6000 00For
Charles Schwab6,5690 00For
Lincoln Financial4,3000 00For
John Hancock3,9950 00For
Guggenheim7470 00For
Victory Capital2700 00For

The compensation paid to the Company's named executive officers, as set forth in the Proxy Statement

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 88,328,168AGAINST: 2,600,932

Prior year: 96.2% for (June 26, 2025 meeting) ▲ 1.0 pts

Details: description as filed, official tally, votes by 101 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

Lineage Cell Therapeutics, Inc.’s own tally for this item (“3. The compensation paid to the Company's named executive officers, as set forth in the Proxy Statement, by the following votes”): 88,328,168 for, 2,600,932 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Shareholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as set forth in the Proxy Statement, by the following votes:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 10 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard7,725,30610 30For
BlackRock1,143,7850 00For
Fidelity607,8180 00For
Goldman Sachs9,7480 00For
BRIDGEWAY FUNDS INC9,6000 00For
Charles Schwab6,5690 00For
Lincoln Financial4,3000 00For
John Hancock3,9950 00For
Guggenheim7470 00For
Victory Capital2700 00For

Fund voting reports, all 10 managers: 9,512,138 for, 10 against, 3 abstained.

Institutional-manager reports: 96 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
FIFTH THIRD BANK, NATIONAL ASSOCIATION4,600,0000 00For
RAFFLES ASSOCIATES LP4,101,4380 00For
BlackRock1,214,1930 00For
GEODE CAPITAL MANAGEMENT, LLC1,129,5700 00For
Northern Trust490,9880 00For
MARSHALL WACE, LLP390,1660 00For
State Street324,2110 00For
Informed Momentum Co LLC217,6460 00For
Fidelity190,9310 00For
Vanguard180,2790 00For
STIFEL NICOLAUS & CO INC \MO\147,1130 00For
Donor Advised Charitable Giving, Inc.00 00Not Voted
Renaissance118,7260 00For
CIBC WORLD MARKET INC.47,0500 00For
TRUST CO OF TOLEDO NA /OH/33,7950 00For
MELLON INVESTMENTS Corp29,7200 00For
Voleon Capital Management LP25,3630 00For
Goldman Sachs24,6530 00For
Two Sigma22,2060 00For
Fifth Third Wealth Advisors LLC20,0000 00For
GC Wealth Management RIA, LLC18,7130 00For
Founders Capital Management16,0000 00For
WELLS FARGO CLEARING SERVICES, LLC15,0110 00For
Fisher Asset Management, LLC13,0960 00For
Piscataqua Savings Bank12,4990 00For

Institutional-manager reports, all 96 managers: 13,551,990 for, 177 against, 130,200 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal…

Official resultAUDIT-RELATEDReported outcome: Approved

99.6% Approved · of votes cast

FOR 99.6%
FOR: 163,825,928AGAINST: 659,670

Prior year: 99.4% for (June 26, 2025 meeting) ▲ 0.2 pts

Details: description as filed, official tally, votes by 10 asset managers

Description as filed by funds: To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.

Lineage Cell Therapeutics, Inc.’s own tally for this item (“2. The appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following votes”): 163,825,928 for, 659,670 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Shareholders ratified the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following votes:”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 10 asset managers below reported 9,512,148 for, 1 against, 1 abstained.

FOR
FOR: 9,512,148AGAINST: 1ABSTAIN: 1
Largest asset managers voting on “To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for our ” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard7,725,3161 10For
BlackRock1,143,7850 00For
Fidelity607,8180 00For
Goldman Sachs9,7480 00For
BRIDGEWAY FUNDS INC9,6000 00For
Charles Schwab6,5690 00For
Lincoln Financial4,3000 00For
John Hancock3,9950 00For
Guggenheim7470 00For
Victory Capital2700 00For

Largest Lineage Cell Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 249,298,295 shares outstanding at the time of that meeting.

Fund voting reports: top Lineage Cell Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 3.10%
2BlackRock 0.46%
3Fidelity 0.24%
4Goldman Sachs <0.01%
5BRIDGEWAY FUNDS INC <0.01%
6Charles Schwab <0.01%
7Lincoln Financial <0.01%
8John Hancock <0.01%
9Guggenheim <0.01%
10Victory Capital <0.01%
Institutional-manager reports: top Lineage Cell Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.”, 2025-2026
#Asset manager % of shares outstanding
1FIFTH THIRD BANK, NATIONAL ASSOCIATION 1.85%
2RAFFLES ASSOCIATES LP 1.65%
3BlackRock 0.49%
4GEODE CAPITAL MANAGEMENT, LLC 0.45%
5Northern Trust 0.20%
6MARSHALL WACE, LLP 0.16%
7State Street 0.13%
8Informed Momentum Co LLC 0.09%
9Fidelity 0.08%
10Vanguard 0.07%

Reported Lineage Cell Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Lineage Cell Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Broadwood Partners, L.P.50,028,620 20.07%Proxy statement (DEF 14A), table as of April 20, 2026
Neal C. Bradsher50,028,620 20.07%Proxy statement (DEF 14A), table as of April 20, 2026
Vanguard Group9,644,276 3.87%Form 13F, quarter ended March 31, 2026
Brian M. Culley8,789,166 3.53%Proxy statement (DEF 14A), table as of April 20, 2026
Millennium Management5,561,374 2.23%Form 13F, quarter ended March 31, 2026
BlackRock3,864,757 1.55%Form 13F, quarter ended March 31, 2026
Geode Capital2,523,114 1.01%Form 13F, quarter ended March 31, 2026
George A. Samuel III2,504,188 1.00%Proxy statement (DEF 14A), table as of April 20, 2026
Renaissance Technologies2,125,100 0.85%Form 13F, quarter ended March 31, 2026
Morgan Stanley1,998,663 0.80%Form 13F, quarter ended March 31, 2026

Percentages above are of 249,298,295 shares outstanding, as reported by Lineage Cell Therapeutics, Inc. on its Form 10-Q dated May 8, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Lineage Cell Therapeutics, Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 101 asset managers reported votes on at least one of its 9 ballot items in their SEC Form N-PX filings, covering 334 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS. — Lineage Cell Therapeutics, Inc.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Lineage Cell Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Lineage Cell Therapeutics, Inc.’s 10-Q dated May 8, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Lineage Cell Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Lineage Cell Therapeutics (LCTX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/lineage-cell-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.